Listen NowDr. Heym gives insight into Total Therapy XVII and why this all important breakthrough in precision medicine and targeted treatment approaches offers the promise of more cures for acute lymphoblastic leukemia and acute lymphoblastic lymphoma patients.
Kenneth Heym, M.D.
Related Information:About the Total Therapy Study XVII at Cook Children'sCook Children's Hematology and Oncology CenterCook Children's Oncology ProgramCook Children's Leukemia and LymphomaCook Children's Hematology and Oncology Clinical Research
Transcript:
00:00:01
Host:  Hello and welcome to Cook Children’s Doc Talk. We're here today with Dr. Kenneth Heym, Medical Director of Cook Children’s Oncology Program. Dr. Heym specializes in the care of children with childhood cancers as well as being the medical director of oncology. Dr. Heym is also very actively involved in research focusing mainly on leukemia and lymphoma and has published several important works on the subject. Dr. Heym, thank you for joining us today to talk about Total Therapy Seventeen, the upcoming clinical trial for children with acute lymphoblastic leukemia or acute lymphoblastic lymphoma.
 00:00:38
Dr. Heym:     Thank you for having me here and it's my pleasure to be able to discuss this exciting work that's going to be something we can be a big part of here at Cook Children's.
 00:00:45
Host:  So can you start by giving us an overview of the Total Therapy Seventeen clinical trial.
 00:00:51
 Dr. Heym:    So acute lymphoblastic leukemia is the most common disease that we treat in childhood cancer. It has gone over the years from a uniformly fatal disease to one in which the vast majority of children will not only be cured of their disease but will go on to have the rest of their life just as before. So Total Therapy Seventeen is the upcoming trial for newly diagnosed patients with acute lymphoblastic leukemia, It is through the St Jude Children's Research Hospital in Memphis Tennessee, now, we have been honored to have an ongoing relationship with St Jude for probably the past twenty years. We participated in other clinical trials with them, We were actually the only institution in the world to participate in the Total Fifteen acute lymphoblastic leukemia protocols so we were the only other hospital that participated in an up front newly diagnosed trial for children with ALL with St Jude. Total Seventeen is really going to be a summary of all that we've learned about leukemia in the last decades really trying to maximize not only the existing therapies that we have for childhood leukemia but also incorporating so much new technology and some of the really cutting edge therapies that are being used, the goal being to cure as many children as possible obviously but also to try to minimize the side effects which can occur both during therapy and long term later in life. The goal is really to try to provide individualized care to each patient.
 00:02:15
 Host:  So you mentioned the long term what are the long-term risks for children?
 00:02:2...

Ver todos los episodios